CRDL Reports $1.2B Revenue, $0.15 EPS, +120% YoY, Launches $500M Buyback, MAVERIC Trial 75% Enrolled
Cardiol Therapeutics Inc. Class A Common Shares · Now $1.22
+3.8% in 3d after detection
Post-detection moves
1h
—
1d
+1.5%
3d
+3.8%
7d
-1.5%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS